SUBSCRIBE
SUBSCRIBE

Cingulate Therapeutics

NEWS
Robert Barrow/MindMed, Ryan Shenvi/Scripps Researc
Drug Development
Innovative Treatments on the Horizon for Anxiety Disorder
MindMed, Scripps Research, Cingulate Therapeutics and the University of Pennsylvania discuss innovative treatments on the horizon for the treatment of anxiety disorder.
June 27, 2022
 · 
8 min read
 · 
Hayley Shasteen
Drug Development
Clinical Catch-Up: 3’s the Charm for Pfizer-BioNTech Vaccine in Kids & More
A roundup of last week’s top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more.
May 27, 2022
 · 
10 min read
 · 
Mark Terry
Deals
Two Biopharmas Nix IPO Plans in Unstable Market
Numerous biopharma and life sciences companies have sought to put their stocks up for sale, but this week, two companies opted to pull out their IPO due to concerns over market stability.
October 21, 2021
 · 
2 min read
 · 
Alex Keown
Deals
Five Life Sciences Companies Ramping up the Fall Flood of IPOs
Experts are predicting a record-breaking rush of IPOs this fall as companies flood to the Nasdaq.
September 13, 2021
 · 
3 min read
 · 
Kate Goodwin
Bio NC
Anxious? Activate Your Anterior Cingulate Cortex With a Little Meditation, Wake Forest University Baptist Medical Center Study
June 5, 2013
 · 
1 min read
JOBS
IN THE PRESS
Press Releases
Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD
May 20, 2025
 · 
8 min read
Press Releases
FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301
May 15, 2025
 · 
6 min read
Press Releases
Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets
May 9, 2025
 · 
10 min read
Press Releases
Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD
April 30, 2025
 · 
7 min read
Press Releases
Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)
April 9, 2025
 · 
6 min read
Press Releases
Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301
April 4, 2025
 · 
6 min read
Press Releases
Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved
March 27, 2025
 · 
12 min read
Press Releases
Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025
March 4, 2025
 · 
9 min read
Press Releases
Final Study Completed for Cingulate’s Lead Asset CTx-1301
January 7, 2025
 · 
7 min read
Press Releases
Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000
December 23, 2024
 · 
3 min read
Load More